PDCD1 and head and neck squamous cell carcinoma: Nivolumab, an anti-PD-1 monoclonal antibody, was the first immunotherapy approved by the FDA for the treatment of HNSCC following a Phase III clinical trial (Checkmate 141, NCT02105636) in 2016 [238].